Miruvor
Sign up
Long COVID Outcome unclear

Long COVID: no help from maraviroc and atorvastatin, later found to be Lyme

Condition
Long COVID
At worst
Not stated
Ill for
Not stated
Last post
Apr 2025
In their words
  • Condition: Long COVIDlikely the cause of my issues over long COVID In context ↗
  • Began after: COVIDmy issues over long COVID
Read from 2 of their posts and comments; links to the 2 this page draws on

Request to remove this story

Summary

A person with long COVID began a maraviroc and atorvastatin protocol in early 2025: 300 mg maraviroc twice daily, 20 mg atorvastatin daily, plus CoQ10 and NAC. After two weeks there was no improvement and few side effects, and by April 2025 they said it had not helped them. They were later diagnosed with Lyme disease, which they thought likely caused their issues. Insurance covered both drugs for under $20 a month.

Ask Miruvor AI

Asking aboutBeacon 93708’s story

What they tried

Their words about each treatment
  • Maraviroc · No changeI’ve been on this regimen for about two weeks, no improvement yet ... Regretfully it did not help me
  • Atorvastatin · No changetaking 300mg Maraviroc twice daily, and 20mg Atorvastatin once daily ... Regretfully it did not help me
  • CoQ10 · Not saidAlso taking a CoQ10 to offset the statin In context ↗
  • NAC · Not saidand an NAC to help protect my liver In context ↗

Their path

They say too little about how ill they were at each step to draw it on the severity scale, so the steps are listed as they describe them. Dates are when they posted.

WhenWhat happened
—long COVIDlikely the cause of my issues over long COVID In context ↗
2025-04-25maraviroc and atorvastatin protocol did not help; diagnosed with Lyme diseaseRegretfully it did not help me, but I have since been diagnosed with Lyme disease In context ↗

Ask Miruvor AI

Asking aboutBeacon 93708’s story

A little hope, every Sunday

New recovery stories and data-driven research on ME/CFS and long COVID. Ideas worth considering, and the evidence behind them.

Free · Unsubscribe anytime